Search

Author/Creator Offidani, M.

1. PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS. (23rd June 2022)

Authors:
Bruzzese, A.; Derudas, D.; Galli, M.; Martino, E. A.; Rocco, S.; Conticello, C.; Califano, C.; Giuliani, N.; Mangicavalli, S.; Farina, G.; Lombardo, A.; Brunori, M.; Rossi, E.; Antonioli, E.; Ria, R.; Zambello, R.; Di Renzo, N.; Mele, G.; Marcacci, G.; Pietrantuono, G.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1856
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. PB2024: PREVALENCE OF TYPE 1 GAUCHER DISEASE IN PATIENTS WITH MULTIPLE MYELOMA: FIRST INTERIM ANALYSIS OF A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY. (23rd June 2022)

Authors:
Offidani, M.; Zizzo, C.; Rupoli, S.; Federici, I.; Bossi, A.; Morè, S.; Manieri, V. M.; Petrucci, M. T.; Caravita di Toritto, T.; Brunori, M.; Gozzetti, A.; Tordi, A.; Fazio, F.; Lisi, C.; Morsia, E.; Corvatta, L.; Olivieri, A.; Duro, G.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1895
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. (8th April 2019)

Authors:
Bringhen, S.; Milan, A.; D'Agostino, M.; Ferri, C.; Wäsch, R.; Gay, F.; Larocca, A.; Offidani, M.; Zweegman, S.; Terpos, E.; Goldschmidt, H.; Cavo, M.; Ludwig, H.; Driessen, C.; Auner, H. W.; Caers, J.; Gramatzki, M.; Dimopoulos, M. A.; Boccadoro, M.; Einsele, H.
Journal:
Journal of internal medicine
Issue:
Volume 286:Number 1(2019)
Page Start:
63
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. S300: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD). (23rd June 2022)

Authors:
D'Agostino, M.; Bringhen, S.; Ria, R.; Ciceri, F.; Falcone, A. P.; Michieli, M.; Grasso, M.; Pane, F.; Quaresima, M.; Cattel, F.; Mirabile, M.; Fioritoni, F.; Petrucci, M. T.; Cotugno, V.; Capra, A.; Pezzatti, S.; Mosca Siez, M. L.; Cantonetti, M.; Margiotta Casaluci, G.; Bertazzoni, P.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
201
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search